Valeo Pharma Inc. Opens the Market
TORONTO, May 9, 2022 /CNW/ - Steve Saviuk, Chief Executive Officer, Frederic Fasano, President and Chief Operating Officer, Luc Mainville, Senior Vice-President and Chief Financial Officer, Valeo Phar...
- Supported exchanges /
- TO /
- VPH.TO
Valeo Pharma Inc (VPH TO) stock market data APIs
C$-0.075
-0.12(-266.7%)
as of October 17, 2024
Price chart is built with Anychart
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.
Valeo Pharma Inc Financial Data Overview
| 0.165 | |
| -0.075 | |
| - | |
| 0.385 | |
| 0.275 | |
| 0.04-0.385 | |
| 4 440 K | |
| 98 657 K | |
| 53 377 K | |
| -0.08 | |
| 2.319 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'VPH',
Type:
'Common Stock',
Name:
'Valeo Pharma Inc',
Exchange:
'TO',
CurrencyCode:
'CAD',
CurrencyName:
'Canadian Dollar',
CurrencySymbol:
'C$',
CountryName:
'Canada',
CountryISO:
'CA',
OpenFigi:
NULL,
ISIN:
'CA91915B1085',
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'October',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Drug Manufacturers - Specialty & Generic',
}
Valeo Pharma Inc Fundamental Data is available in our Financial Data APIs
- Net Revenue 53 377 K
- EBITDA -14 099 000
- Earnings Per Share -0.37
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Valeo Pharma Inc Earnings via APIs
- Latest Release 2024-09-12
- EPS/Forecast -0.05
Get Valeo Pharma Inc End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Valeo Pharma Inc latest news via APIs
VALEO PHARMA ANNOUNCES LISTING OF CONVERTIBLE DEBENTURES ON TSX
MONTREAL, April 19, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, is pleased to announce that the 12% Conver...
- MATURITY DATE
- PHARMA
- VALEO PHARMA
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
